

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived mouse GDF-15 protein
Ser189-Ala303
Accession # Q9Z0J7.2

N-terminal Sequence Analysis Ser189

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 13 kDa

SPECIFICATIONS

SDS-PAGE 11-13 kDa, under reducing conditions,

Activity Measured by its binding ability in a functional ELISA.
Recombinant Mouse GDF-15 (CHO-expressed) (Catalog # 10596-GD) binds to Recombinant Mouse GFR α -like Fc Chimera (Catalog # 9844-GR) with an ED₅₀ of 0.500-5.00 ng/mL.

Endotoxin Level <0.10 EU per 1 μ g of the protein by the LAL method.

Purity >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 μ m filtered solution in HCl. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 500 μ g/mL in 4 mM HCl.


Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA


Binding Activity



Recombinant Mouse GDF-15 (ng/mL)

Recombinant Mouse GDF-15 (CHO-expressed) Protein Binding Activity. In a functional ELISA, Recombinant Mouse GDF-15 (CHO-expressed) (Catalog # 10596-GD) binds to Recombinant Mouse GFR α -like Fc Chimera (Catalog # 9844-GR) with an ED₅₀ of 0.500-5.00 ng/mL.


Bioactivity



Recombinant Mouse GDF-15 (ng/mL)

Recombinant Mouse GDF-15 (CHO-expressed) Protein Bioactivity. Recombinant Mouse GDF-15 (Catalog # 10596-GD) activates SRE-SEAP reporter in HEK293 human embryonic kidney cells transfected with human c-Ret and human GFRAL.

SDS-PAGE



Recombinant Mouse GDF-15 (CHO-expressed) Protein SDS-PAGE. 1 μ g/lane of Recombinant Mouse GDF-15 (CHO-expressed) Protein (Catalog # 10596-GD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing bands at 11-13 kDa and 22-26 kDa, respectively.

BACKGROUND

Growth Differentiation Factor 15 (GDF-15), also called Macrophage inhibitory cytokine-1 (MIC-1), placental transforming growth factor-beta, prostate-derived factor, and placental bone morphogenetic protein, is a divergent member of the transforming growth factor beta (TGF-beta) superfamily. GDF-15 is highly expressed in placenta and is expressed at lower levels in kidney, pancreas, prostate and colon. It is also widely expressed in brain. Similarly to other TGF-beta family proteins, GDF-15 is synthesized as a large precursor protein that is cleaved at the dibasic cleavage site (RXXR) to release the carboxy-terminal domain. The carboxy-terminal domain of GDF-15 contains the characteristic seven conserved cysteine residues necessary for the formation of the cysteine knot and the single interchain disulfide bond. Furthermore, the carboxy-terminal domain contains two additional cysteine residues that form a fourth intrachain disulfide bond. Biologically active GDF-15 is a disulfide-linked homodimer of the carboxy-terminal 112 amino acid residues. Mature mouse GDF-15 shares 59.6% and 91.9% amino acid sequence similarity with human and rat GDF-15, respectively. GDF-15 has been shown to have various functions, including inhibition of production of tumor necrosis factor alpha (TNF-alpha) from lipopolysaccharide-stimulated macrophages, induction of cartilage formation, early-stage endochondral bone formation, and promotion of neuronal survival. GDF-15 is the functional ligand for the receptor GFRAL, facilitating weight-loss functions of the protein through c-Ret downstream signaling. GFRAL and GDF-15 signaling is implicated in diet-based obesity and insulin resistance (8-10).

References:

1. Bootcov, M.R. *et al.* (1997) *Proc. Natl. Acad. Sci. USA* **94**:11514.
2. Böttner, M. *et al.* (1999) *Gene* **237**:105.
3. Fairlie, W.D. *et al.* (1998) *J. Leukoc. Biol* **65**:2.
4. Fairlie, W.D. *et al.* (2001) *J B.C* **20**:16911.
5. Bauskin, A.R. *et al.* (2000) *EMBO J.* **19**:2212.
6. Strelau, J. *et al.* (2000) *J. Neurosci.* **20**:8597.
7. Schober, A. *et al.* (2001) *J. Comp. Neurol.* **439**:32.
8. Mullican, S. *et al.* (2017) *Nat. Med* **23**:1150.
9. Yang, L. *et al.* (2017) *Nat. Med* **23**:1158.
10. Emmerson, P. *et al.* (2017) *Nat. Med* **23**:1215.